bims-myxlip Biomed News
on Myxoid liposarcoma
Issue of 2026–03–01
two papers selected by
Laura Mannarino, Humanitas Research



  1. Pathol Oncol Res. 2026 ;32 1612284
       Objectives: Fluorescence in situ hybridization (FISH) break-apart probes are widely employed to detect gene rearrangements in malignant tumors. Notwithstanding their utility, the complex genetic alterations in tumors frequently give rise to isolated signals, the mechanisms underlying which remain poorly understood. This study aimed to elucidate the genetic causes of isolated FISH signals in lymphoma and myxoid liposarcoma samples, providing a more accurate basis for interpreting FISH results.
    Methods: Six cases of lymphoma and myxoid liposarcoma, which showed isolated signals for BCL2, MYC, BCL6, or DDIT3 in FISH detection, were carefully screened. Whole genome resequencing (WGR) was employed to analyze the genetic variations present in these samples. In addition, immunohistochemistry was used to assess the expression levels of the corresponding proteins in these samples.
    Results: WGR results revealed that all six cases with isolated signals harbored target gene translocations, with 5'and 3'probe-binding region deletions or inversions detected in BCL2, MYC, and BCL6, and in the 5'probe-binding region of DDIT3. Additionally, overexpression of the corresponding proteins was present in samples with isolated BCL2, MYC, and BCL6 signals.
    Conclusion: Deletions or inversions in the probe-binding sequence regions may disrupt probe recognition and binding, leading to isolated FISH signals for BCL2, MYC, BCL6, and DDIT3. Notably, in cases with isolated BCL2, MYC, or BCL6 signals, translocations involving these genes were associated with increased expression of their encoded proteins. These findings improve the understanding of FISH signal interpretation in tumor gene rearrangement detection and provide a valuable reference for clinical diagnosis.
    Keywords:  break-apart probe; fluorescence in situ hybridization; gene rearrangement; isolated signal; lymphoma; myxoid liposarcoma
    DOI:  https://doi.org/10.3389/pore.2026.1612284
  2. Int J Cancer. 2026 Feb 24.
      Soft-tissue sarcomas (STS) comprise over 150 histological subtypes, with advanced cases showing poor prognosis (5-year survival <10%). Trabectedin, a synthetic alkaloid, is frequently used after anthracycline-based chemotherapy failure. Despite the withdrawal of reimbursement in France in 2016 due to debated efficacy and safety, it remains in clinical use, imposing financial strain on hospitals. This retrospective single-center study evaluated trabectedin's efficacy, safety, and cost in 68 patients treated between 2019 and 2023. L-sarcomas accounted for 78% of cases, including uterine leiomyosarcomas (n = 16), soft-tissue leiomyosarcomas (n = 17), and myxoid liposarcomas (n = 8). Non-L-sarcomas (22%) included mostly synovial sarcomas. The overall disease control rate was 71%, with a median progression-free survival (PFS) of 4.1 months, and an overall survival of 12.3 months. Subtype-specific median PFS was 6.8 months for liposarcomas (11.3 for myxoid vs. 4.5 for other subtypes), 3.1 months for leiomyosarcomas (3.4 months for uterine vs. 3.1 for soft-tissue), and 2.4 months for non-L-sarcomas. Patients received a median of 5 cycles (range: 1-38), with an average total dose of 16 mg [2-81], and an average hospital cost of €9900. Adverse events occurred in 91%, mainly hematological; cardiac toxicity was seen in 9%. This retrospective single-center study in a limited cohort provides real-world insights but should be interpreted with caution. Despite limited reimbursement, trabectedin may retain clinical utility, particularly in L-sarcoma management.
    Keywords:  drug‐related side effects and adverse events; health care economics and organizations; sarcoma; trabectedin; treatment outcome
    DOI:  https://doi.org/10.1002/ijc.70403